PathAI, Inc. Overview
Pro stress-test →PathAI is an AI-powered pathology company that uses machine and deep learning to improve the accuracy of diagnosis and treatment efficacy of diseases like cancer. The company develops AI software and digital pathology systems used in diagnostic workflows, clinical research, and drug development, with tools that analyze tissue samples and pathology images to support biomarker discovery and disease characterization.
Strategic Profile
Pro stress-test →PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Its AISight® platform is a cloud-native enterprise workflow solution used by leading laboratories and research centers to power digital pathology workflows and AI applications, serving as a central hub for case management, image management, and artificial intelligence tools. The company collaborates with healthcare organizations, pathology laboratories, and biopharmaceutical companies to support precision medicine and pathology digitization initiatives.
Competitive Landscape
Pro stress-test →PathAI has $106.7M in reported revenue and raised $165M in Series C funding in 2021, competing against rivals such as Paige and Proscia in the specialized AI software for pathology market. Other noted competitors in digital pathology include Philips, Proscia, and Ibex.
Industry Context
PathAI, Inc. operates in AI-powered digital pathology.
Key facts
Founded: 2016 · Headquarters: Boston, Massachusetts · Revenue: $106.7M · Market cap: N/A